ESTRO 2025 - Abstract Book

S1012

Clinical – Head & neck

ESTRO 2025

2045

Digital Poster The utility of F-18 FDG PET-CT imaging in the work-up and management of salivary gland malignancies Yashna Nadkarni 1,2 , Garima Gupta 1,3 , Kathryn Wallitt 1,4 , Dorothy Gujral 1,2,5 1 Head and Neck Unit, Imperial College Healthcare NHS Trust, London, United Kingdom. 2 Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom. 3 Department of Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom. 4 Department of Nuclear Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom. 5 Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, United Kingdom Purpose/Objective: Positron emission tomography – computed tomography with 18F-fluorodeoxyglucose (F-18 FDG PET-CT) imaging in the work-up of patient with salivary gland malignancies is not currently a clinical standard. We sought to determine the utility of this imaging modality in the work-up of these patients and whether this results in a change in management. Material/Methods: We retrospectively reviewed consecutive patients with salivary gland malignancies who were planned for radical treatment with surgery +/- adjuvant (chemo)radiotherapy. All patients had ultrasound and MRI neck with contrast +/- contrast-enhanced CT scan chest abdomen and pelvis as part of their work-up, as well as F-18 FDG PET-CT either prior to surgery or before adjuvant treatment at the clinician’s discretion. We recorded the proportion of patients where F-18 FDG PET-CT resulted in upstaging and led to a change in initial management plan. Results: Between 01/2012 and 05/2024, 27 patients (14 (51.9%) female) were treated for salivary gland malignancy with F-18 FDG PET-CT work-up. Patient characteristics are listed in Table 1. 22 (81%) patients had F-18 FDG PET-CT prior to surgery and 5(19%) patients were scanned before adjuvant treatment. Fourteen (52%) patients were node-positive and had intermediate to high grade tumours (85%). All patients had been planned for radical treatment but, after F 18 FDG PET-CT, 6 (22%) of patients were diagnosed with metastatic disease (Figure 1) and treated with palliative intent. 19 (70% of patients had no change in management after F-18 FDG PET-CT, 2 (8%) were upstaged to dual modality (surgery + postoperative radiotherapy) treatment, and 6 (22%) were upstaged to triple modality Surgery + postoperative chemoradiotherapy.